Phapros reports 311.58% rise in third-quarter net profit
The Indonesian pharmaceutical company posted higher margins, with January–September EBITDA reaching Rp117.66 billion.
Indonesian pharmaceutical company PT Phapros Tbk (PEHA) reported third-quarter 2026 net profit of Rp31.60 billion, an increase of 311.58%. Sales for January–September reached Rp786.57 billion, up 15.07% from Rp683.58 billion a year earlier.
EBITDA for the first nine months rose 30.26% to Rp117.66 billion. The EBITDA margin reached 15%, compared with 13.2% in the corresponding period of 2025. Gross profit increased 19.19% to Rp402.53 billion, while the gross margin widened from 49.4% to 51.2%.
Cost of goods sold increased 11.04% to Rp384.04 billion over the nine months, against Rp345.86 billion a year earlier. As a proportion of sales, those costs fell from 50.6% to 48.8%.
President director Intan Abdams Katoppo attributed the performance to stronger working capital, tighter cost controls, improvements to the product and business portfolio, and changes to systems and processes introduced in 2025. In remarks cited on 2 November 2026, she expressed optimism that the positive financial trend would continue through year-end.
Pre-tax profit climbed 233.59% to Rp48.65 billion from Rp14.58 billion. Net operating cash flow increased 142.85% to Rp129.96 billion, while cash and cash equivalents stood at Rp157.54 billion on 30 September 2026, up 70.54% from Rp92.38 billion a year earlier.
